Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVA-203
- Development stage
- Preclinical
- Lead developer
- Biovista
- Modality
- Small Molecules
01
Overview
BVA-203 is a small molecule drug candidate developed by Biovista for the treatment of Leber's Hereditary Optic Neuropathy (LHON). As a repositioned drug, it is an existing pharmaceutical agent being developed for a new indication, which provides it with an established safety profile and favorable pharmacokinetics. The drug's mechanism of action involves the modulation of oxidative stress-related mechanisms, providing antioxidant protection to cells. In preclinical studies using primary human fibroblasts from LHON patients, BVA-203 demonstrated statistically significant protective effects against oxidative insult, outperforming idebenone. It is currently in the advanced preclinical stage and is available for licensing.
Beyond the preview
Go deeper on BVA-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVA-203.